TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: skin barrier recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: self-reported fat, fruit and vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst visual analog scale pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pethidine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first pethidine injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: meal-stimulated gastric acid secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Score differences on the Flanker Inhibitory Control and Attention Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative nausea and vomiting (PONV)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall costs of anesthesia
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: recurrent low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT dispersion (QTd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: JT dispersion (JTd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial Stiffness (AIx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: days off school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: PPWA decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement or clinical unchanged status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pupillary dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriateness of breaking bad news
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tibialis anterior muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: overall muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ability to light cure a simulated restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy delivered to a simulated restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of skill after instruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative major morbidity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of correct fruit names
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to reduce alcohol consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean operative time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain scores (visual analog scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to readmission for a new pulmonary exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pulmonary arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression-free survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: volume voided during urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal cystomanometry volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal bladder pressure during ODC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal calprotectin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death from prostate cancer (PCa)
Endpoint domain: Mortality/survival
Primary endpoint: Bioavailability of gatifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete control of established postoperative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in level of sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fistula breakdowns
Endpoint domain: Adverse events/effects
Primary endpoint: non-fistula-related incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: urinary retention after repair
Endpoint domain: Adverse events/effects
Primary endpoint: minimum weight loss achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometriosis growth and symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal rates during treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of symptoms after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Severity Scale score mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability of Arm, Shoulder and Hand Questionnaire score mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Status Scale score mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reduction during IV cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IV cannulation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: prevention of maternal malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reduction of neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: Response to thalidomide therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to pulmonary, liver, or bone marrow failure
Endpoint domain: Mortality/survival
Primary endpoint: Dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Antifactor Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: proportion of patients requiring rescue analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: total consumption of rescue analgesic
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: plasma triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved arterial endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Less thickening of the carotid wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma vitamin B6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum vitamin B12 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage weight gain within the first 48 hours of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak postprandial increment in plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean intraocular pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive outcomes (mean NPZ-7 change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Information processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: early minimum lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vaginal cuff closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: tibial shaft bone strength index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: rejection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CSDD mood subscale treatment effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of antibiotic prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: increased or unchanged morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doxorubicin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 2 and 3 stomatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Median absolute granulocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-procedural infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Re-hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Valid diagnosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma choline status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle choline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coefficient of fat absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic and diastolic arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of burning sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: confidence of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful expectant management of ectopic pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDADI total scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postsurgical time to first bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence rate of toxic and adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Immune function (CD4+ T cell levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fat oxidation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal openings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyst dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBT scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to patient controlled analgesia (PCA) discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first solid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total VSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: success rate of LSR monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Central Corneal Thickness (CCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects achieving greater than moderate pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yearly inpatient spending
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in glucose-lowering medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AHA scores maintenance or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New onset of co-occurring conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Study satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Longest continuous days of abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard of dropping out of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Time of cycling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion abstinent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion improved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving effective prophylaxis for venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DST-Forward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DST-Backward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of pupils eating FV daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of teachers offering FV daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAQ DI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 PCS improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acceptability of treatment delivery method
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: exercise‐induced bronchoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: exhaled nitric oxide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: recurrent otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cerebral blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulated relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: weekly number of days with at least 1 hour of brisk leisure PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of students meeting PA recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of students reporting that their family sets limitations for screen time
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: isometric grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: workplace sitting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed graft function (DGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Estimated glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relief of episodic heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in antacid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oswestry Disability Index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall drowsiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: short-term verbal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recognition of Words
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: monitor response and relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wrinkle reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in pores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cardiovascular thrombotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death from cardiovascular causes
Endpoint domain: Mortality/survival
Primary endpoint: percentage of wound slough over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of dressing changes at week 12
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average wound area after 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wound radius decrease per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of any ipsilateral stroke
Endpoint domain: Mortality/survival
Primary endpoint: combined disabling or fatal ipsilateral stroke
Endpoint domain: Mortality/survival
Primary endpoint: risk of occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Expression of Treg and Th17
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of IL-17, IL-6, and IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: major complications rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: whitening outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluorescence intensity (FI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission risk
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean lesion depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved family functioning
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: greater satisfaction with therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Salivary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAS (Total Antioxidant Status)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VASP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRS-R total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of nitric oxide, F2‐isoprostane, and lipid peroxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oxidative stress outcomes
Primary endpoint: Serum total glutathione (GSH) contents and activities of GSH‐peroxidase and GSH‐s‐transferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oxidative stress outcomes
Primary endpoint: Immune‐related cytokines (interleukin‐12 and interferon‐γ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes